Phase 3 Readout

IMNN: Phase 3 Topline: A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combinati

Name: Phase 3 Topline: A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combinati
Start: 2032-10-31
End: 2032-10-31

October 31, 2032. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 31, 2032
Company: Imunon, Inc. (IMNN)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combinati

October 31, 2032

IMNN overview →

Company: Imunon, Inc. (IMNN)
Indication: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma